Previous close | 6.26 |
Open | 6.46 |
Bid | 6.47 x 1400 |
Ask | 5.99 x 100 |
Day's range | 6.23 - 6.55 |
52-week range | 4.05 - 9.94 |
Volume | |
Avg. volume | 25,667 |
Market cap | 116.751M |
Beta (5Y monthly) | -0.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.63 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 24 May 2022 |
1y target est | 20.00 |
ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript March 15, 2024 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.27. PRPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Noella Alexander-Young: Hello, and good […]
NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase’s business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: FY 2023 Financial Results Update: For the fiscal year ending December 31, 2023
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday March 15, 2024, at 11:00 AM ET Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or t